Minireviews

Targeting Epigenetic Mechanisms for Chronic Pain: A Valid Approach for the Development of Novel Therapeutics

Casey O. Ligon, Rachel D. Moloney, and Beverley Greenwood-Van Meerveld

Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (C.O.L., R.D.M., and B.G.-V.M.); and the Veterans Affairs Medical Center, Oklahoma City, Oklahoma (B.G.-V.M.)

Received December 22, 2015; accepted January 15, 2016

ABSTRACT

Chronic pain is a multifaceted and complex condition. Broadly classified into somatic, visceral, or neuropathic pain, it is poorly managed despite its prevalence. Current drugs used for the treatment of chronic pain are limited by tolerance with long-term use, abuse potential, and multiple adverse side effects. The persistent nature of pain suggests that epigenetic machinery may be a critical factor driving chronic pain. In this review, we discuss the latest insights into epigenetic processes, including DNA methylation, histone modifications, and microRNAs, and we describe their involvement in the pathophysiology of chronic pain and whether epigenetic modifications could be applied as future therapeutic targets for chronic pain. We provide evidence from experimental models and translational research in human tissue that have enhanced our understanding of epigenetic processes mediating nociception, and we then speculate on the potential future use of more specific and selective agents that target epigenetic mechanisms to attenuate pain.

Introduction

Acute pain signals real or potential tissue damage, making it an important protective sensation that influences behavior to prevent further injury and promote healing. Acute pain can be mild or severe, with a relatively short duration, and typically resolves with the treatment or healing of the damaged tissue. By contrast, chronic pain is a pathologic state that does not serve a protective function and is considered harmful to the organism. Defined as pain persisting for 6 months after the resolution of, or in the absence of, an injury, chronic pain affects approximately one-fifth of adults in the United States and is associated with a significantly reduced quality of life and an increased risk of mental health disorders (Breivik et al., 2006; Tsang et al., 2008; Goldberg and McGee, 2011). The economic effects of chronic pain are equal to that of cancer and heart disease, with an estimated cost of $300 billion in the United States alone (Institute of Medicine, 2011).

Although current therapeutics are effective at relieving acute pain, drugs used to manage chronic pain are typically ineffective, with the development of novel pharmacologic therapies experiencing little progress in recent decades. Indeed, chronic pain is still predominantly treated with two classes of drugs: nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. Both NSAIDs and opioids, along with other adjuvant therapies, can provide limited relief, and unfortunately, these treatments are frequently associated with harmful side effects.

The precise mechanisms underlying the transition from acute to chronic pain are not well understood, although adaptations in numerous structures within pain pathways, such as peripheral neurons, dorsal root ganglia (DRG), spinal cord neurons, and the brain, are known to be involved (Woolf and Salter, 2000; Kuner, 2010). This plasticity, which is essential for the development of chronic pain, involves significant changes in neurotransmitters and other molecules, cells, and neural networks and is maintained, in part, by epigenetic processes (Graeff et al., 2011; Buchheit et al., 2012; Karpova, 2014). Indeed, epigenetic processes, comprising DNA methylation, chromatin remodeling, and noncoding RNA, have been increasingly implicated in the development of chronic pain in recent years, thus highlighting new potential targets for drug development and pain management.

Although current therapeutics are effective at relieving acute pain, drugs used to manage chronic pain are typically less efficacious, with the development of novel pharmacologic therapies experiencing little progress in recent decades. Indeed, chronic pain is still predominantly treated with two classes of drugs: nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. Both NSAIDs and opioids, along with other adjuvant therapies, can provide limited relief, and unfortunately, these treatments are frequently associated with harmful side effects.

The precise mechanisms underlying the transition from acute to chronic pain are not well understood, although adaptations in numerous structures within pain pathways, such as peripheral neurons, dorsal root ganglia (DRG), spinal cord neurons, and the brain, are known to be involved (Woolf and Salter, 2000; Kuner, 2010). This plasticity, which is essential for the development of chronic pain, involves significant changes in neurotransmitters and other molecules, cells, and neural networks and is maintained, in part, by epigenetic processes (Graeff et al., 2011; Buchheit et al., 2012; Karpova, 2014). Indeed, epigenetic processes, comprising DNA methylation, chromatin remodeling, and noncoding RNA, have been increasingly implicated in the development of chronic pain in recent years, thus highlighting new potential targets for drug development and pain management.

Although current therapeutics are effective at relieving acute pain, drugs used to manage chronic pain are typically less efficacious, with the development of novel pharmacologic therapies experiencing little progress in recent decades. Indeed, chronic pain is still predominantly treated with two classes of drugs: nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. Both NSAIDs and opioids, along with other adjuvant therapies, can provide limited relief, and unfortunately, these treatments are frequently associated with harmful side effects.

The precise mechanisms underlying the transition from acute to chronic pain are not well understood, although adaptations in numerous structures within pain pathways, such as peripheral neurons, dorsal root ganglia (DRG), spinal cord neurons, and the brain, are known to be involved (Woolf and Salter, 2000; Kuner, 2010). This plasticity, which is essential for the development of chronic pain, involves significant changes in neurotransmitters and other molecules, cells, and neural networks and is maintained, in part, by epigenetic processes (Graeff et al., 2011; Buchheit et al., 2012; Karpova, 2014). Indeed, epigenetic processes, comprising DNA methylation, chromatin remodeling, and noncoding RNA, have been increasingly implicated in the development of chronic pain in recent years, thus highlighting new potential targets for drug development and pain management.

Although current therapeutics are effective at relieving acute pain, drugs used to manage chronic pain are typically less efficacious, with the development of novel pharmacologic therapies experiencing little progress in recent decades. Indeed, chronic pain is still predominantly treated with two classes of drugs: nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. Both NSAIDs and opioids, along with other adjuvant therapies, can provide limited relief, and unfortunately, these treatments are frequently associated with harmful side effects.

The precise mechanisms underlying the transition from acute to chronic pain are not well understood, although adaptations in numerous structures within pain pathways, such as peripheral neurons, dorsal root ganglia (DRG), spinal cord neurons, and the brain, are known to be involved (Woolf and Salter, 2000; Kuner, 2010). This plasticity, which is essential for the development of chronic pain, involves significant changes in neurotransmitters and other molecules, cells, and neural networks and is maintained, in part, by epigenetic processes (Graeff et al., 2011; Buchheit et al., 2012; Karpova, 2014). Indeed, epigenetic processes, comprising DNA methylation, chromatin remodeling, and noncoding RNA, have been increasingly implicated in the development of chronic pain in recent years, thus highlighting new potential targets for drug development and pain management.

Although current therapeutics are effective at relieving acute pain, drugs used to manage chronic pain are typically less efficacious, with the development of novel pharmacologic therapies experiencing little progress in recent decades. Indeed, chronic pain is still predominantly treated with two classes of drugs: nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. Both NSAIDs and opioids, along with other adjuvant therapies, can provide limited relief, and unfortunately, these treatments are frequently associated with harmful side effects.
the small number of other drugs that do not fall into these categories, produce a number of adverse side effects and, critically, often fail to provide adequate long-term relief in many chronic conditions (Johnson and Greenwood-Van Meerveld, 2014). Given these limitations, the need for improved therapeutic options for the management of chronic pain is apparent.

This review briefly summarizes the pathways of chronic pain, categorized as somatic, visceral, or neuropathic pain, and the currently available therapies. We then describe the primary mechanisms of epigenetic regulation and review the recent findings in the field of epigenetics and chronic pain. Finally, we discuss the epigenetic drugs and their usefulness in the context of pain management and highlight the potential approaches for targeting epigenetic mechanisms in a specific and selective manner.

**Chronic Pain**

Chronic pain pathways involve stimuli originating from skin, skeletal muscle, joints, or visceral organs. These pathways and the mechanisms of their sensitization have been expertly described in several excellent reviews (Besson, 1999; Almeida et al., 2004; Wilder-Smith, 2011; Woolf, 2011). Briefly, the classic acute pain pathway involves the activation of primary nociceptive afferents within the periphery, which then send the stimulus to the dorsal horn of the spinal cord (Almeida et al., 2004). After synapsing with the dorsal horn, the signal is then transmitted across the midline to the anterolateral tract of the spinal cord, where it ascends to the thalamus in the brain. From the thalamus, the signal is relayed to the somatosensory cortex for localization. Ascending nociceptive signals traveling via the spinoparabrachial and spinoreticular tract activate limbic structures, such as the amygdala, to produce an emotional response to the stimulus. The remaining constituent regions of the central pain matrix (prefrontal cortex, cingulate, and parietal cortex) define the magnitude and quality of the pain signal. Pathways composed of motor cortex and brain stem areas are then activated, contributing to descending modulation of the pain signal. Although the exact mechanisms vary depending on site and pathology, sensitization of this acute pain pathway occurring at the level of the periphery, spinal cord, or central pain matrix leads to the development of chronic pain. In the periphery, after tissue damage or immune stimulation, primary afferent nociceptors are sensitized due to the release of a myriad of algesic molecules (cytokines, histamine, prostaglandins, substance P, etc.) by local tissue or immune cells participating in the healing process. In addition, activation of G protein–coupled receptors on the primary afferent nociceptors induces second-messenger pathways that change intracellular calcium, modify existing receptors, and alter receptor expression, all of which lead to further sensitization of the nociceptor. The second site of sensitization occurs within the dorsal horn of the spinal cord, where the sensitized primary nociceptive afferent releases neurotransmitters [including glutamate, substance P, brain-derived neurotrophic factor (BDNF), and others] that stimulate the second-order neuron. Sensitization is promoted through changes in gene regulation that shift the balance of receptors, leading to an increased excitability of the neuron—through changes in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, potassium, and metabotropic glutamate receptors. The final hypothesized mechanism that produces chronic pain is supraspinal hypersensitivity. Central sensitization at the level of supraspinal sites, specifically regions encompassing the pain matrix discussed above (thalamus, prefrontal cortex, amygdala), alter the descending control of pain responses and thus maladaptive, chronic nociceptive behaviors occur (Cervero, 1995, 2000). Indeed, brain imaging studies have revealed not only gross structural changes (decreased gray matter, cortical thickness) (DaSilva et al., 2008; Cauda et al., 2014) but altered connectivity between regions in this matrix (Ellingson et al., 2013; Mansour et al., 2013; Irinia et al., 2015). Moreover, it has been proposed that long-term potentiation and thus plasticity occurs to maintain central sensitization (Reichling and Levine, 2009; Luo et al., 2014).
on the histone residue modified. For instance, H3K4, K36, and K79 methylation is indicative of active transcriptional states, whereas methylated H3K9 and H4K20 are signifiers of condensed and inactive chromatin (Ng et al., 2009). It is important to note that genes can demonstrate both active and repressive modifications, representing a poised state requiring additional external cues to promote either increased expression or gene silencing.

There a number of enzymes dedicated to modifying histones. Histone acetyltransferases (HATs) are responsible for transferring acetyl groups to histone tail lysine residues. Acetylation is reversed by histone deacetylases (HDACs).
There are four known classes of HDACs: the zinc-dependent classes I, II, and IV, and class III (or sirtuins), which are NAD-dependent (Géranton and Tchiki, 2015b). Similarly, there are several known enzymes dedicated responsible for methylating histone residues. Histone methyltransferases generally fall into two classes: lysine methyltransferases and the less well understood protein arginine N-methyltransferases (Izzo and Schneider, 2010). Initially thought to be an irreversible modification, histone methylation has been shown to be a dynamic process, with the recent discovery of a number of histone demethylases (Cloos et al., 2008).

**DNA Modifications.** Another key epigenetic mechanism of chromatin regulation and, consequently, gene expression is methylation of cytosines in genomic DNA to produce 5-methylcytosine. Cytosine methylation occurs predominantly at CpG dinucleotides, particularly those within intergenic regions and repetitive sequences such as long and short interspersed nuclear elements (Zamudio and Bourc'his, 2010). Typically, methylation in the regulatory regions of promoters silences gene transcription by preventing transcription factor binding or by recruiting gene-silencing complexes. However, DNA methylation is not an exclusively repressive mark. As with histone modifications, DNA methylation is a complex mechanism that has been shown to promote both gene activation and silencing depending on the surrounding epigenome (Smith and Meissner, 2013).

DNA methylation occurs via DNA methyltransferases (DNMTs). DNMT1 is responsible for the maintenance of methylation patterns as cells divide, whereas DNMT3A and DNMT3B are the enzymes that engage in de novo DNA methylation in response to environmental cues (Smith and Meissner, 2013). DNA demethylation, however, is a much more complex process and is much less understood. DNA methylation was long thought a static mechanism but it has recently been recognized as a more plastic process after the identification of demethylation-mediating proteins such as Gadd45a and the ten-eleven translocation (TET) family proteins, among others (Chen and Riggs 2011).

**Evidence for Epigenetic Changes in Preclinical Studies of Pain**

In recent years, a significant amount of research examining the involvement of epigenetic processes in human disease has been conducted, resulting in the development of a handful of novel therapeutic agents that target these processes. However, the science of pain epigenetics is still very much in its infancy, with understanding of the links between epigenetics and the transition to, and maintenance of, chronic pain only beginning to emerge (Fig. 1). Consequently, it is not yet clear whether targeting these epigenetic mechanisms is a practical method by which chronic pain can be managed.

**Somatic Pain.** Most studies investigating epigenetic mechanisms involved in chronic somatic pain have been performed in animal models of inflammatory pain. Generally, inflammation-induced histone modifications contribute to hypersensitivity via dysregulation of HDAC and HAT activity and expression, resulting in hypoacetylation at promoter regions of antinociceptive genes or genes critical to proper pain circuit functionality and the silencing of these genes (Zhang et al., 2011). In the case of DNA methylation, inflammation is capable of inducing hypermethylation at the promoter region of antinociceptive genes and consequently silencing these genes (Pan et al., 2014). Other studies have observed hypomethylation of pronociceptive genes and, therefore, increased expression of those genes in models of inflammatory pain (Qi et al., 2013). Alterations in the levels of epigenetic enzymes such as methylated CpG binding proteins have also been reported in models of inflammatory pain (Zhang et al., 2014).

Epigenetic modifying enzymes themselves (i.e., HDACs, HATs) have also implicated in somatic pain modulation and can affect downstream expression of both pro- and antinociceptive genes. Crow et al. (2015) showed that HDAC4 was essential for appropriate transcriptional responses after injury. Expression of pronociceptive genes Calc and transient receptor potential cation channel subfamily V member 1 (Trpv1) was consistently lower within the DRG sensory neurons in HDAC4 conditional knockout animals compared with their littermate controls (Crow et al., 2015). Furthermore, this downregulation of HDAC4 reduced the sensitivity to capsaicin in vitro and reduced thermal hypersensitivity in the complete Freund’s adjuvant (CFA) model of inflammatory pain (Crow et al., 2015). The CFA model has also revealed changes in specific miRNAs. CFA significantly reduced mRNA-219 expression in mice spinal neurons, with bisulfite sequencing revealing CFA-induced hypermethylation of CpG islands in the miR-219 promoter (Pan et al., 2014). Moreover, overexpression of spinal miR-219 prevented and reversed thermal hyperalgesia and mechanical allodynia (Pan et al., 2014).

Other gene targets shown to be epigenetically regulated in the CFA model include BDNF, whereby histone H3 acetylation at the bdnf gene promoter was reduced significantly 3 days after CFA injection, with concomitant increases in bdnf mRNA levels and BDNF protein levels (Tao et al., 2014). Others have implicated cystathionine-β-synthetase in the pathophysiology of CFA-induced inflammatory pain in which its promoter was differentially methylated in DRG samples from inflamed rats versus controls (Qi et al., 2013). Further examination revealed significant upregulation of methyl-binding domain protein 4 and growth arrest and DNA damage-inducible protein 45α in inflamed rats (Qi et al., 2013), further implicating DNA methylation as a key mechanism underlying CFA-induced inflammatory pain. A translational study of note that examines DNA methylation utilized a rodent model of lower back pain and reported DNA methylation-induced downregulation of SPARC (secreted protein, acidic, rich in cysteine), an extracellular matrix protein that has been linked to age-dependent disc degeneration (Tajerian et al., 2011).

The most commonly investigated drugs in the context of chronic somatic pain are HDAC inhibitors. Studies indicate that HDAC inhibition or the promotion of histone acetylation in these models is typically analgesic. A study by Zhang et al. (2011) showed that 3 days after intraplantar CFA administration, animals exhibited decreased acetylated H3 at the Gad2 promoter in the nucleus raphe magnus of the brain resulting in the downregulation of GAD65, an enzyme essential for normal GABAergic neuron functionality. After repeated infusion of HDAC inhibitors such as trichostatin A (TSA) or suberoylanilide hydroxamic acid (SAHA) into the nucleus raphe magnus, CFA-induced thermal hyperalgesia was attenuated and H3 acetylation at Gad2 was restored.
A second study utilizing a mouse CFA pain model found that inflammation promoted upregulation of class II HDACs and downregulation of acetylated H3K9/K18 in the spinal cord. These epigenetic changes, along with inflammatory thermal hyperalgesia, could be prevented with a single intrathecal dose of a number of class II HDAC inhibitors 30 minutes prior to CFA administration or reversed with an intrathecal dose of these inhibitors at 1, 5, and 25 hours after CFA administration (Bai et al., 2010). Treatment with demethylation agent 5′-aza-2′-deoxycytidine (5-aza) has also shown efficacy in the CFA model, with marked reductions in pain behavior and spinal neuronal sensitization (Pan et al., 2014); however, further data on the therapeutic potential of DNA methylation are limited.

**Visceral Pain.** Few studies have addressed the epigenetics of chronic visceral pain. Similar to somatic pain, evidence suggests that the maintenance of chronic visceral pain is a combination of histone modifications and DNA methylation at various levels of the pain pathway. For example, studies investigating models of stress or pharmacologically induced visceral hypersensitivity have found changes in acetylated histone-promoter interactions in the brain and spinal cord and concomitant dysregulation of the related pro- and antinociceptive genes in these tissues (Tran et al., 2013, 2015; Hong et al., 2015). Similarly, stress-induced visceral pain has also been linked to alterations in DNA methylation patterns within the brain, leading to increased expression of pronociceptive neurotransmitters (Tran et al., 2013).

There have also been some recent insights into the role that miRNAs play in experimental visceral pain models of chronic cystitis and esophageal reflux disease, with several miRNAs identified in the development of chronic visceral pain (Sengupta et al., 2013; Zhang and Banerjee, 2015). However, evidence directly linking these miRNAs to visceral pain behaviors is currently lacking. In another study, Zhou et al. (2009) investigated the effects of miR-29 on increased intestinal permeability, which has previously been associated with visceral hypersensitivity (Zhou and Verne, 2011; Camilleri et al., 2012). After experimentally inducing colitis or exposing wild-type mice to a stressor they observed an upregulation of miR-29a and miR-29b along with increased intestinal permeability in these animals. In *MiR-29^−/−* mice, however, this colitis- or stress-induced intestinal permeability was greatly diminished. Finally, in microarray and permeability experiments, they showed that miR-29a/b target Claudin-1 and nuclear factor-κB–repressing factor mRNA for degradation, thus increasing intestinal permeability (Zhou et al., 2015a).

HDAC inhibitors are the most common epigenetic drugs to be investigated as potential therapeutics for chronic visceral pain. The studies examining HDAC inhibitors report that these drugs significantly improve outcomes in these models. Intrathecal administration of SAHA to rats with 17β-estradiol–induced visceral hypersensitivity stimulated hyperacetylation of H3 and increased binding of H3K9ac to the promoter region of the metabotropic glutamate receptor 2 gene *Grm2*. This increased association between H3K9ac and *Grm2*, in conjunction with binding of activated estrogen receptor α, leads to the upregulation of metabotropic glutamate receptor 2 in the spinal cord and the attenuation of visceral hypersensitivity (Cao et al., 2015). Tran et al. (2013) showed that visceral hypersensitivity in rats resulting from chronic water avoidance stress could be prevented by daily intracerebroventricular infusions of TSA during the course of the stress paradigm.

In a second study, this group used a pharmacologically induced model of visceral hypersensitivity to examine histone deacetylation in the brain. This study showed that prolonged exposure of the central nucleus of the amygdala (CeA) to corticosterone to produce visceral hypersensitivity is associated with deacetylation of H3K9 and its decreased association with the 177 region of the glucocorticoid receptor (GR) promoter within the CeA, leading to a downregulation of GR and, in turn, upregulation of the pronociceptive corticotropin releasing factor. Bilateral infusions of TSA and SAHA into the CeA reversed these changes to the epigenome and attenuated visceral hypersensitivity (Tran et al., 2015). Another study examining the role of epigenetic modulation of GR in visceral pain showed that water avoidance stress increases methylation of the GR promoter and reduces its expression in a regional-specific manner in DRG neurons. The authors also found that stress upregulated DNMT1-associated methylation of the cannabinoid receptor promoter, increased expression of the HAT EP300, increased histone acetylation at the TRPV1 promoter, and increased expression of the TRPV1 receptor in DRG neurons. They also showed that knockdown of both DNMT1 and EP300 in L6-S2 DRG neurons reduced both DNA methylation and histone acetylation, respectively, which prevented stress-induced visceral pain (Hong et al., 2015). Finally, chronic visceral hypersensitivity induced by early-life stress has been shown to induce histone deacetylation in the lumbosacral spinal cord, with maternally separated rats showing a decrease in H4K12 acetylation that correlated with visceral hypersensitivity in adulthood. Moreover, peripheral treatment with SAHA attenuated the stress-induced effects (Moloney et al., 2015).

**Neuropathic Pain.** Many studies have investigated epigenetic modulation in models of neuropathic pain. To date, most have focused on histone modifications and report changes at all levels of the pain pathway. Typically, nerve injury induces alterations in acetylation status of H3 and H4, leading to the dysregulation of a myriad of genes responsible for proper neuronal function and pain perception. For example, the upregulation of pronociceptive genes has been linked to histone hyperacetylation in the spinal cord after nerve injury (Zhu et al., 2014). Other studies have shown that injury causes neuroinflammation-induced neuropathic pain through marked histone modifications and increased expression of multiple proinflammatory genes in leukocytes infiltrating the injured tissue (Kiguchi et al., 2012, 2013). Injury-induced neuropathic pain has also been linked to histone hypoacetylation in the DRG, which leads to decreased expression of genes essential to C-fiber functionality (Matsushita et al., 2013). In addition to changing histone acetylation patterns, nerve injury also alters histone methylation. Specifically, Laumet et al. (2015) showed that spinal nerve ligation (SNL) decreases the expression of several potassium channels and their related genes through increased expression of the histone methyltransferase G9a, resulting in neuropathic pain symptoms.

As with the previously outlined studies, HDAC inhibitors and HAT inhibitors are the most commonly used epigenetic drugs in neuropathic pain studies. Although the mechanisms underlying the various models of neuropathic pain are varied...
and complex, the administration of HDAC inhibitors has generally produced positive outcomes in regard to pain behaviors. It has been demonstrated that partial sciatic nerve ligation (PSNL)–induced hypoesthesia could be prevented by administration of the HDAC inhibitors valproate and TSA. The investigators report that PSNL downregulates ion channels Nav1.8 and Kv4.3, which are extensively involved in pain perception, as well as TRPV1, transient receptor potential cation channel subfamily M member 8, and calcitonin gene-related peptide gene expression in DRGs. Pretreatment with HDAC inhibitors maintained H3 and H4 acetylation at these genes, thereby promoting their expression and normal C-fiber functionality (Matsushita et al., 2013). Another study showed that intrathecal administration of HDAC inhibitor MS-275 (N’-[4-[[2-aminophenyl]amino][carbonyl][phenyl][methyl]-3-pyridinylmethyl]ester, carboxamidc acid) prevented SNL-induced mechanical and thermal hyperalgesia by increasing acetylation of H3K9 and altering HDAC1 expression in the dorsal horn of the spinal cord (Denk et al., 2013). Finally, valproate attenuated SNL-induced mechanical hyperalgesia via the restoration of glutamate transporter-1 in the spinal cord, although the authors did not specifically investigate epigenetic changes in this study (Yoshizumi et al., 2013). HAT inhibitors have also proven to be particularly effective at improving outcomes in models of neuropathic pain. After PSNL, the HAT inhibitor anacardic acid reportedly decreased acetylation of H3K9 at the promoters of macrophage inflammatory protein 2 and CXC chemokine receptor type 2 in macrophages and neutrophils infiltrating the injured tissue, thereby attenuating PSNL-induced thermal hyperalgesia (Kiguchi et al., 2012). The same authors also demonstrated that CC-chemokine ligands 2 and 3, two other important contributors to peripheral sensitization after injury, could be downregulated by anacardic acid through a similar epigenetic mechanism involving H3K9 and H3K4me3 (Kiguchi et al., 2013).

In a separate study, the chronic constriction injury (CCI) rat model revealed that p300 (transcriptional coactivator and HAT E1A binding protein) expression was increased in the lumbar spinal cord on day 14 after CCI. The treatment with intrathecal p300 short hairpin RNA or C646 (4-[4-[4-[5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl]methyl]ene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]benzoic acid), an inhibitor of p300 acetyltransferase, reversed CCI-induced mechanical allodynia and thermal hyperalgesia (Zhu et al., 2012). This work was then expanded on in a following study wherein curcumin, which has known HAT inhibitory properties, was shown to effectively attenuate neuropathic pain by silencing pronociceptive genes Bdnf and cyclooxygenase (COX)-2 by reducing the binding of p300/CREB-binding protein, H3K9ac, and H4K5ac to their promoters (Zhu et al., 2014). To date, only one study has investigated the effects of targeting DNA methylation in the context of neuropathic pain models. This study primarily focused on the use of 5-aza to antagonize DNMTs after injury, and the authors showed that 5-aza attenuated mechanical and thermal hyperalgesia by reversing CCI-induced expression of methyl CpG binding protein 2 and global DNA methylation (Wang et al., 2011).

Several studies have examined the effects of targeting specific ncRNAs in the treatment of neuropathic pain, although only a few have directly linked the expression of these RNAs to pain behavior. Sakai and Suzuki (2014) observed a decrease in miR-7a in the DRGs of SNL and CCI rats. Using an adeno-associated virus vector to restore miR-7a in DRGs, they were able to attenuate mechanical and thermal hypersensitivity in both models and identified the β2 subunit of the voltage-gated sodium ion channel as a potential target for miR-7a (Sakai and Suzuki, 2014). Another investigation showed that miR-103 expression was decreased in the dorsal horn of SNL rats, whereas the expression of the Cav1.2–comprising L-type calcium channel was that knocked down of miR-103 using small interfering RNA in naïve rats results in mechanical hypersensitivity. Moreover, intrathecal administration of miR-103 significantly reduced SNL-induced hypersensitivity (Favereaux et al., 2011). IncRNAs have also been implicated as contributors to neuropathic pain. Specifically, the IncRNA identified as antisense RNA for voltage-dependent potassium channel Kcna2 mRNA was increased in the DRGs of SNL rats. Mimicking this increase in Kcna2 antisense in naïve animals produced neuropathic pain symptoms, whereas blocking the increase attenuated the development of nerve injury–induced neuropathic pain (Zhao et al., 2013).
found to be significantly increased in the whole blood of patients with IBS versus healthy controls (Fourie et al., 2014). Both of these miRNAs are implicated in pain processes and inflammation. In another condition characterized by severe visceral pain, Wu et al. (2006) proposed that endomiosis is an epigenetic disease, showing that the promoter region of progesterone receptor β, but not progesterone receptor α, is hypermethylated. Moreover, Wu et al. (2005) previously showed aberrant methylation of HOXA10 in the eutopic endometrium of women with endomiosis. Although these findings do not directly involve pain circuitry, they provide further evidence for altered epigenetic processes in chronic pain disorders.

In patients with lower back pain caused by disc degeneration, reduced SPARC expression was apparent in the intervertebral discs and DNA methylation was altered (Tajerian et al., 2011). The authors show that within the promoter region of the SPARC gene, there are significant increases in DNA methylation, which may underpin decreases in the SPARC gene expression. Following on from this ex vivo work, the authors performed in vitro experiments aimed to further tease apart the exact mechanism, showing that methylation of both the human and murine promoter silences SPARC promoter activity (Tajerian et al., 2011).

**Current Approaches to Treat Chronic Pain**

As alluded to earlier, the etiology of chronic pain is complex and thus treatment has many obstacles due to its persistent nature. Current therapeutic approaches have modest efficacy and poor side effect profiles and often fail short in directly treating the underlying pathologic nociceptive signaling. NSAIDs are the most common treatment for both acute pain and chronic pain. These compounds act through inhibition of COX-1 and COX-2 activity, thus preventing the synthesis of prostaglandins and thromboxanes (Buvanendran and Lipman, 2010; Buvanendran, 2013). Some of the most commonly used NSAIDs include aspirin, ibuprofen, ketoprofen, and naproxen. The most typical side effects of NSAIDs include heartburn and nausea. However, in the context of chronic pain, frequent or long-term use of NSAIDs may lead to stomach ulcers or high blood pressure. Acetaminophen is another widely used pain medication with a mode of action that includes inhibition of COX-1 and COX-2 (Graham et al., 2013). However, acetaminophen is not classified as an NSAID because it exhibits only modest anti-inflammatory activity. However, when administered in combination with opioid analgesics, acetaminophen is used in the management of more severe pain. Although it is well tolerated,

### TABLE 1
Summary of HDAC and DNMT inhibitors

<table>
<thead>
<tr>
<th>Epigenetic Modifier</th>
<th>Classification</th>
<th>Compound</th>
<th>Chemical Name</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDAC inhibitors</td>
<td>Hydroxamates</td>
<td>SAHA</td>
<td>(E)-N-hydroxy-3-[4-(phenylsulfonyl)phenoxy]prop-2-enamide</td>
<td>Pan inhibitor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FXD101</td>
<td>(E)-N-hydroxy-3-[4-[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenylprop-2-enamide</td>
<td>Pan inhibitor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LBH589</td>
<td>(E)-N-hydroxy-3-[4-[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenylprop-2-enamide</td>
<td>Classes I and II</td>
</tr>
<tr>
<td></td>
<td>Cyclic peptides</td>
<td>ITF2357</td>
<td>[6-(diethylaminomethyl)naphthalene-2-yl]methyl-N-[4-(hydroxycarbamoyl)phenyl]carbamate·hydrate·hydrochloride</td>
<td>Pan inhibitor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4SC-201</td>
<td>(E)-3-[1-[4-[dimethylamino]methyl]phenyl]sulfonylpyrrol-3-yl]-N-hydroxyprop-2-enamide</td>
<td>Pan inhibitor</td>
</tr>
<tr>
<td></td>
<td>Aliphatic fatty acids</td>
<td>PCI-24781</td>
<td>3-[dimethylamino]methyl]-N-[2-[4-(4-hydroxycarbamoyl)phenoxyl]ethyl]-1-benzofuran-2-carboxamide</td>
<td>Classes I and II</td>
</tr>
<tr>
<td></td>
<td>Benzamides</td>
<td>MS-275</td>
<td>N-[4-[[2-aminoaryl]lumino]carbonyl]phenyl)methyl]-3-pyridinylmethyl ester, carboxamic acid</td>
<td>Class I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MGCD0103</td>
<td>N-[2-(aminophenyl)-4-[[4-pyridin-3-yl]pyrimidin-2-yl]amino]methyl]benzamide</td>
<td>Class I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M344</td>
<td>4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide</td>
<td>Class I</td>
</tr>
<tr>
<td></td>
<td>Unknown mechanism</td>
<td>CI-994</td>
<td>4-acetamido-N-[2-aminophenyl]benzamide</td>
<td>Classes I and II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BML-210</td>
<td>N'-[2-aminophenyl]-N'-phenolotanediamide</td>
<td>HDAC 1–5 and 7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NVP-LAQ824</td>
<td>(E)-N-hydroxy-3-[4-[2-(2-hydroxyethyl)-2,1H-indol-3-yl]ethyl]amino]methyl]phenylprop-2-enamide</td>
<td>Unknown</td>
</tr>
<tr>
<td>DNMT inhibitors</td>
<td>5-Azacitidine</td>
<td></td>
<td>Pan inhibitor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5-aza-2'-deoxycytidine</td>
<td></td>
<td>Pan inhibitor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1β-o-arabinofuranosylβ-azacytosine</td>
<td></td>
<td>Pan inhibitor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dihydro-5-azacytidine</td>
<td></td>
<td>DNMT1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MG98</td>
<td></td>
<td>Pan inhibitor</td>
<td></td>
</tr>
</tbody>
</table>
acetaminophen can alter liver function when combined with alcohol, and acute overdoses of acetaminophen can cause potentially fatal liver damage (Jaeschke et al., 2014).

For moderate to severe chronic pain, opioidergic compounds (de Leon-Casasola, 2013), including morphine and oxycodone, are typically prescribed. Working through the µ-δ heterodimer, these compounds are generally effective (Pasternak and Pan, 2011). However, common side effects, including constipation, dizziness, lightheadedness, drowsiness, nausea, and vomiting, severely limit their usefulness. More importantly, the long-term daily use of opioid analgesics leads to physical dependence and even hyperalgesia (Bruehl et al., 2013).

Alternative approaches for chronic pain management include antidepressants (serotonin-norepinephrine reuptake inhibitors), calcium channel blockers, α2-adrenergic receptor agonists, and GABA receptor agonists (Eisenberg and Peterson, 2010; Jackson and Argoft, 2010; Murinson, 2013; Nicholson, 2013). A spectrum of side effects is associated with these compounds; the most common include sedation, dizziness, dry mouth, edema, withdrawal symptoms if discontinued, and severe hypotension. Taken together, the current treatment options for chronic pain are unsatisfactory with low efficacy and are associated with a host of adverse side effects, thus the necessity for the development of novel therapeutics remains an urgent medical need.

**Epigenetic Modifiers as Therapeutic Targets for Chronic Pain**

Epigenetics offers the opportunity to remodel an aberrant signaling cascade, which may underpin the persistent experience of pain. Over the last 2 decades, there has been rapid advancement of pain genetics and these studies have provided a solid foundation for the emergence of pain epigenetics. However, there are still many obstacles to overcome to develop this concept into an effective treatment approach. Here we will summarize the potential of epigenetic therapies but also the current limitations. The concept of using epigenetic therapies for the treatment of chronic pain remains unproven but evidence to date suggests that this approach may offer more benefit to patients over the current analgesic regimens. Identifying a specific epigenetic mark or landscape that is unique to the disease state is critical for the development of an effective therapy. The idea that an epigenetic therapeutic that could target a specific pathway to rectify the underlying cause of chronic pain, as opposed to simply treating the symptom, is very attractive. Identifying a discrete epigenetic signature, which is responsible for chronic pain in a patient population, and designating compounds to directly target this signature would undoubtedly be a huge advancement in the field. Epigenetic drugs offer the opportunity to rectify the underlying pathology of chronic pain and not just attenuate the symptom.

Currently, the application and availability of epigenetic-based therapies used clinically for a variety of disorders and diseases is limited. Both HDAC inhibitors and DNMT inhibitors are being investigated as anticancer agents; however, therapies for the treatment of non–life-threatening states of persistent pain have yet to be developed. Therapies that manipulate single epigenetic marks that subsequently target a specific gene should be considered for development. Over the last decades, investigators focused on single gene expression differences or mutations that are involved in nociception. Future approaches should focus on the development of locally acting therapeutics targeting the epigenetic mechanism(s) that have been identified to contribute to chronic pain. For example, identifying specific genes within the nociceptive circuitry will allow us to use tools such as small interfering RNA to target the aberrant gene in a discrete manner. Moreover, the epigenome itself could be targeted with designer DNA binding proteins developed from transcriptional activator-like effectors or zinc finger proteins (Day, 2014). The use of miRNA-based therapies is also of interest. Indeed, a limited number of studies have identified specific miRNAs that are altered in chronic pain and are amenable to manipulation via mimics to induce analgesic effects (Sun et al., 2012; Willemen et al., 2012; Pan et al., 2014; Lu et al., 2015).

The current epigenetic modifying compounds are nonspecific and nonselective, acting both centrally and peripherally as well as at many epigenetic sites. The changes in the epigenome during the development of persistent pain are also extraordinarily complex and dynamic. Moreover, the resulting epigenetic mark largely depends on the injury or insult sustained as well as the past experiences of each individual. With this in mind, the current epigenetic drugs in development and in use for the treatment of cancer (Copeland et al., 2009; New et al., 2012) that may potentially be investigated in the context of pain are highly nonspecific HDAC inhibitors and DNMT inhibitors (summarized in Table 1), which have numerous side effects and seem unsuitable for long-term treatment of chronic pain.

**Summary**

Chronic pain represents a large unmet medical need and it is clear that alternative therapies are required with novel mechanisms of action. Having reviewed the primary mechanisms of epigenetic regulation and the recent findings in the field of epigenetics and chronic pain, it is apparent that new therapies targeting epigenetic marks represent a legitimate approach. However, this strategy for treating chronic pain is currently limited by the paucity of selective compounds with a side effect profile that is suitable to support chronic use by patients often with non–life-threatening but severely debilitating chronic pain. Thus, continuing to build upon our knowledge of genetic and epigenetic mechanisms in pain pathways will undoubtedly aid in our understanding and development of novel therapeutics to treat chronic pain disorders.

**Authorship Contributions**

Wrote or contributed to the writing of the manuscript: Ligon, Moloney, Greenwood-Van Meerfeld.

**References**


